Oneness Biotech Co

Oneness Biotech Co Net Margin

The Net Profit Margin of Oneness Biotech Co (4743.TWO) as of Oct 30, 2026 is -809.13 %. In the previous year, Net Profit Margin was -988.03 % — a change of -18.11% (higher).

Net Margin

-809.13 %

YoY

-18.11%

Last updated:

Net Profit Margin of Oneness Biotech Co is 2025 -809.13 % . Net Profit Margin of Oneness Biotech Co was 2024 -988.03 % . It decreases by -18.11% higher compared to the previous year.

For Oneness Biotech Co, the net margin of -809.1% is down versus -627.7% a few years ago.

The Oneness Biotech Co Net Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Margin
Date
Net Margin
Jan 1, 2018
-1,248.60 TWD
Jan 1, 2019
-2,437.57 TWD
Jan 1, 2020
-604.92 TWD
Jan 1, 2021
-627.72 TWD
Jan 1, 2022
33.78 TWD
Jan 1, 2023
-1,512.82 TWD
Jan 1, 2024
-988.03 TWD
Jan 1, 2025
-809.13 TWD
The Oneness Biotech Co Net Margin history
YEARNet MarginYoY
-809.13 %-18.11%
-988.03 %-34.69%
-1,512.82 %-4,578.05%
33.78 %-105.38%
-627.72 %+3.77%
-604.92 %-75.18%
-2,437.57 %+95.22%
-1,248.60 %-79.22%
-6,008.74 %+2,303.58%
-249.99 %-78.93%
-1,186.29 %-132.54%
3,645.30 %+5,981.81%
59.94 %-1,981.29%
-3.19 %-184.81%
3.76 %+23,194.06%
0.02 %-99.58%
3.85 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Oneness Biotech Co Stock analysis

What does Oneness Biotech Co do? Oneness Biotech Co., Ltd. generates revenue through the research and development of new drugs and the sale of pharmaceutical products and health products. The company focuses on health supplies, health food, and healthy food as its main products, which are distributed domestically. It also develops new drugs for treating chronic diabetic foot ulcers and anticancer drugs, targeting the domestic market for both its existing and new product lines. The firm's primary customers are domestic consumers seeking health and pharmaceutical solutions, including those requiring wound healing treatments for diabetic foot ulcers and anticancer therapies. Its product portfolio includes health supplies, health food, healthy food, and specialized drug developments, all sold within Taiwan's domestic market. Oneness Biotech's business model centers on developing and selling health and pharmaceutical products, with a particular emphasis on niche medical applications like diabetic foot ulcer treatments and cancer drugs. The company leverages its domestic distribution network to reach consumers interested in health-focused solutions and specialized medical treatments. Oneness Biotech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Oneness Biotech Co stock

Net Profit Margin of Oneness Biotech Co is -809.13 % in 2025.

Net Profit Margin of Oneness Biotech Co changed from -988.03 % to -809.13 %, representing a -18.11% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Profit Margin Oneness Biotech Co since 2006 – with annual values, charts, and detailed analysis.

Net Margin measures the percentage of revenue that becomes net profit after all expenses. It is the ultimate measure of a company's profitability.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Profit Margin's Oneness Biotech Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Net Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Net Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — Oneness Biotech Co

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — Oneness Biotech Co